Literature DB >> 19183160

Time trends in peptic ulcer, erosive reflux oesophagitis, gastric and oesophageal cancers in a multiracial Asian population.

K-L Goh1, H-T Wong, C-H Lim, M S Rosaida.   

Abstract

BACKGROUND: Dramatic changes in the prevalence and pattern of gastrointestinal disease has taken place in Asia in recent years. AIM: To compare the prevalence of duodenal (DU) and gastric ulcers (GU), erosive oesophagitis (EO), gastric cancer (GCA) and oesophageal cancer (OCA) and Helicobacter pylori infection over a 10-year interval of time in a multiracial South-East Asian population.
METHODS: Endoscopy records of first time gastroscopy in the University of Malaya Medical Centre, Kuala Lumpur, Malaysia were reviewed for 1989/1990 and 1999/2000.
RESULTS: In the period of 1989-1990, 3252 records and in 1999-2000, 4615 records were analysed. Both DU (21.1-9.5%) and GU (11.9-9.4%) had decreased significantly (P < 0.001). EO had increased significantly from 2.0% to 8.4% (P < 0.001). Both GCA and OCA had declined in the 10-year interval. Helicobacter pylori prevalence had decreased from 51.7% to 30.3% (P < 0.001).The decrease in DU and GU was seen in all racial groups. The increase in EO was most marked in Indians and the decrease in GCA in Chinese. The proportion of H. pylori-associated DU and GU had also decreased with time.
CONCLUSIONS: Peptic ulcers and H. pylori infection had declined over a 10-year period of time and showed an opposing time trend with EO, which had increased dramatically. Both GCA and OCA had declined in prevalence.

Entities:  

Mesh:

Year:  2009        PMID: 19183160     DOI: 10.1111/j.1365-2036.2009.03930.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

Review 1.  Does Helicobacter pylori infection protect against esophageal diseases in Asia?

Authors:  Justin C Y Wu
Journal:  Indian J Gastroenterol       Date:  2011-08-26

2.  Time trends in epidemiology of peptic ulcer disease in India over two decades.

Authors:  Amit Kumar Dutta; Ashok Chacko; Avinash Balekuduru; Manoj Kumar Sahu; Sajith Kattiparambil Gangadharan
Journal:  Indian J Gastroenterol       Date:  2012-07-06

3.  Interobserver reliability in the endoscopic diagnosis and grading of Barrett's esophagus: an Asian multinational study.

Authors:  Y C Lee; M B Cook; S Bhatia; W H Chow; E M El-Omar; H Goto; J T Lin; Y Q Li; P L Rhee; P Sharma; J J Sung; J Y Wong; J C Wu; K Y Ho
Journal:  Endoscopy       Date:  2010-08-30       Impact factor: 10.093

4.  Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China.

Authors:  Zhuolin Zhang; Yuwen Bao; Lele Cai; Yajie Gu; Ting Yang; Xin Li
Journal:  Clin Drug Investig       Date:  2022-08-22       Impact factor: 3.580

5.  Psychological factors influence the gastroesophageal reflux disease (GERD) and their effect on quality of life among firefighters in South Korea.

Authors:  Seung-Ho Jang; Han-Seung Ryu; Suck-Chei Choi; Sang-Yeol Lee
Journal:  Int J Occup Environ Health       Date:  2016-10-03

6.  The changing pattern of upper gastrointestinal disorders by endoscopy: data of the last 40 years.

Authors:  Erkan Caglar; Birol Baysal; Ahmet Dobrucalı
Journal:  Diagn Ther Endosc       Date:  2014-09-08

7.  Systematic investigation of gastrointestinal diseases in China (SILC): validation of survey methodology.

Authors:  Xiaoyan Yan; Rui Wang; Yanfang Zhao; Xiuqiang Ma; Jiqian Fang; Hong Yan; Xiaoping Kang; Ping Yin; Yuantao Hao; Qiang Li; John Dent; Joseph Sung; Duowu Zou; Saga Johansson; Katarina Halling; Wenbin Liu; Jia He
Journal:  BMC Gastroenterol       Date:  2009-11-19       Impact factor: 3.067

8.  Association of sleep dysfunction and emotional status with gastroesophageal reflux disease in Korea.

Authors:  Ji Yeon Kim; Nayoung Kim; Pyoung Ju Seo; Jung Won Lee; Min Soo Kim; Sung Eun Kim; So Young Jo; Dong Ho Lee; Hyun Chae Jung
Journal:  J Neurogastroenterol Motil       Date:  2013-07-08       Impact factor: 4.924

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.